SB 249417

an inhibitory anti-factor IX(a) monoclonal antibody for the treatment of thromboembolic stroke

Also Known As:

SB249417

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SB 249417: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SB 249417: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        SB 249417: 2

Experts

1.	Barone, Frank C: 1 article (02/2002)
2.	Gabriel, Melanie A: 1 article (02/2002)
3.	Hart, Timothy K: 1 article (02/2002)
4.	Koster, Paul F: 1 article (02/2002)
5.	McVey, Matt: 1 article (02/2002)
6.	Ohlstein, Eliot H: 1 article (02/2002)
7.	Parsons, Andrew A: 1 article (02/2002)
8.	Toomey, John R: 1 article (02/2002)
9.	Valocik, Richard E: 1 article (02/2002)
10.	Blackburn, M N: 1 article (10/2000)

Related Diseases

1.	Thrombosis (Thrombus) 10/01/2000 - "Pretreatment of rats with either SB 249417 (3.0 mg/kg, i. v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resulted in comparable and significant reductions in thrombus formation. " 10/01/2000 - "A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. " 10/01/2000 - "Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis."
2.	Stroke (Strokes) 02/01/2002 - "Treatment with SB 249417 (3.0 mg/kg) 2, 4, or 6 hours after stroke reduced infarct volumes by 44%, 50%, and 13% (P=NS), respectively. " 02/01/2002 - "In this study, using a rat thromboembolic stroke model, we investigated the use of an inhibitory anti-factor IX(a) monoclonal antibody (SB 249417) for the treatment of thromboembolic stroke and compared its efficacy to that of tPA. "
3.	Brain Ischemia (Cerebral Ischemia) 02/01/2002 - "This study suggests that cerebral ischemia and the resultant perfusion deficit are exacerbated by the activation of blood coagulation and that anticoagulants like SB 249417 may find utility in the treatment of ischemic stroke."
4.	Ischemic Stroke 02/01/2002 - "This study suggests that cerebral ischemia and the resultant perfusion deficit are exacerbated by the activation of blood coagulation and that anticoagulants like SB 249417 may find utility in the treatment of ischemic stroke."
5.	Infarction (Infarctions) 02/01/2002 - "Treatment with SB 249417 (3.0 mg/kg) 2, 4, or 6 hours after stroke reduced infarct volumes by 44%, 50%, and 13% (P=NS), respectively. "

Related Drugs and Biologics

1.	Factor IX (Coagulation Factor IX)
2.	Monoclonal Antibodies
3.	Enoxaparin (Lovenox)
4.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
5.	Anticoagulants